All Updates

All Updates

icon
Filter
Funding
Halda Therapeutics raises USD 126 million in extended Series B funding to support clinical trials for drug candidates targeting prostate and breast cancer
Precision Medicine
Aug 12, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Partnerships
Geographic expansion
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Precision Medicine

Precision Medicine

Aug 12, 2024

Halda Therapeutics raises USD 126 million in extended Series B funding to support clinical trials for drug candidates targeting prostate and breast cancer

Funding

  • Halda Therapeutics has raised USD 126 million in an extended Series B funding round, with participation from new investors RA Capital Management, Deep Track Capital, Frazier Life Sciences, Vida Ventures, Boxer Capital, Taiho Ventures, and existing investors Canaan Partners, Connecticut Innovations, Access Biotechnology, and Elm Street Ventures.

  • The funds are expected to support the clinical trials of two regulated induced proximity targeting chimeras (RIPTAC) drug candidates targeting metastatic prostate and breast cancer. Halda’s lead therapeutic, HLD-0915, is expected to begin a Phase I trial in early 2025 for metastatic, castration-resistant prostate cancer (mCRPC). The funds will also support a second RIPTAC therapeutic for metastatic breast cancer and will help expand the company's team and product pipeline.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.